Prognostic Impact of Blood Lipid Profile in Patients With Advanced Solid Tumors Treated With Immune Checkpoint Inhibitors: A Multicenter Cohort Study
Specific components of lipid profile seem to differently impact on immune activity against cancer and unraveling their prognostic role in patients with solid cancer treated with immune checkpoint inhibitors (ICIs) is needed. We retrospectively collected baseline clinicopathological characteristics i...
Gespeichert in:
| Veröffentlicht in: | The oncologist (Dayton, Ohio) Ohio), 2024-03, Vol.29 (3), p.e372-e381 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e381 |
|---|---|
| container_issue | 3 |
| container_start_page | e372 |
| container_title | The oncologist (Dayton, Ohio) |
| container_volume | 29 |
| creator | Pecci, Federica Cantini, Luca Cognigni, Valeria Perrone, Fabiana Mazzaschi, Giulia Agostinelli, Veronica Mentrasti, Giulia Favari, Elda Maffezzoli, Michele Cortellini, Alessio Rossi, Francesca Chiariotti, Rebecca Venanzi, Francesco Maria Lo Russo, Giuseppe Galli, Giulia Proto, Claudia Ganzinelli, Monica Tronconi, Francesca Morgese, Francesca Campolucci, Carla Moretti, Marco Vignini, Arianna Tiseo, Marcello Minari, Roberta Rocchi, Marco Luigi Bruno Buti, Sebastiano Berardi, Rossana |
| description | Specific components of lipid profile seem to differently impact on immune activity against cancer and unraveling their prognostic role in patients with solid cancer treated with immune checkpoint inhibitors (ICIs) is needed.
We retrospectively collected baseline clinicopathological characteristics including circulating lipid profile (total cholesterol [TC], triglycerides [TG], low-density lipoproteins [LDL], high-density lipoproteins [HDL]) of patients with consecutive solid cancer treated with ICIs, and we investigated their role in predicting clinical outcomes.
At a median follow-up of 32.9 months, among 430 enrolled patients, those with TC ≥ 200 mg/dl showed longer median progression-free survival (mPFS; 6.6 vs. 4.7 months, P = .4), although not reaching statistical significance, and significantly longer median overall survival (mOS; 19.4 vs. 10.8 months, P = .02) compared to those with TC |
| doi_str_mv | 10.1093/oncolo/oyad273 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10911919</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A791557019</galeid><sourcerecordid>A791557019</sourcerecordid><originalsourceid>FETCH-LOGICAL-c458t-2f5502b9cde403bd8eb4652f158b9a37179b15dc600ca6d0fc44181d8545c97b3</originalsourceid><addsrcrecordid>eNptkkFvFCEYhidGY2v16tGQePEyLQzDzODFrBurm6yxSdfojTDA7KAzfFNgmuwP6f-V7a6NJg0HvsDzvbzAm2WvCT4nmNMLcAoGuICd1EVNn2SnhJU8Lzn--TTVuKF5TRg_yV6E8AvjVNLieXZC65pXDW1Os7srD1sHIVqFVuMkVUTQoY8DgEZrO1mNEtDZwSDr0JWM1rgY0A8be7TQt9Ipo9E1DInbzCP4gDbeyJgW75HVOM7OoGVv1O8JrIto5Xrb2pjI92iBvs5DOjhJGo-W0IOP6DrOevcye9bJIZhXx_ks-375abP8kq-_fV4tF-tclayJedExhouWK21KTFvdmLasWNER1rRc0prUvCVMqwpjJSuNO1WWpCG6YSVTvG7pWfbhoDvN7Wj03omXg5i8HaXfCZBW_L_jbC-2cCvS2xPCCU8K744KHm5mE6IYbVBmGKQzMAdRNHVZVBTTKqFvD-hWDkZY10GSVHtcLGpOGKvxveD5I1Qa2oxWgTP7z3i0QXkIwZvuwT7Be59UHDIijhlJDW_-vfQD_jcU9A_drrw7</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2874263036</pqid></control><display><type>article</type><title>Prognostic Impact of Blood Lipid Profile in Patients With Advanced Solid Tumors Treated With Immune Checkpoint Inhibitors: A Multicenter Cohort Study</title><source>DOAJ Directory of Open Access Journals</source><source>Oxford Journals Open Access Collection</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Pecci, Federica ; Cantini, Luca ; Cognigni, Valeria ; Perrone, Fabiana ; Mazzaschi, Giulia ; Agostinelli, Veronica ; Mentrasti, Giulia ; Favari, Elda ; Maffezzoli, Michele ; Cortellini, Alessio ; Rossi, Francesca ; Chiariotti, Rebecca ; Venanzi, Francesco Maria ; Lo Russo, Giuseppe ; Galli, Giulia ; Proto, Claudia ; Ganzinelli, Monica ; Tronconi, Francesca ; Morgese, Francesca ; Campolucci, Carla ; Moretti, Marco ; Vignini, Arianna ; Tiseo, Marcello ; Minari, Roberta ; Rocchi, Marco Luigi Bruno ; Buti, Sebastiano ; Berardi, Rossana</creator><creatorcontrib>Pecci, Federica ; Cantini, Luca ; Cognigni, Valeria ; Perrone, Fabiana ; Mazzaschi, Giulia ; Agostinelli, Veronica ; Mentrasti, Giulia ; Favari, Elda ; Maffezzoli, Michele ; Cortellini, Alessio ; Rossi, Francesca ; Chiariotti, Rebecca ; Venanzi, Francesco Maria ; Lo Russo, Giuseppe ; Galli, Giulia ; Proto, Claudia ; Ganzinelli, Monica ; Tronconi, Francesca ; Morgese, Francesca ; Campolucci, Carla ; Moretti, Marco ; Vignini, Arianna ; Tiseo, Marcello ; Minari, Roberta ; Rocchi, Marco Luigi Bruno ; Buti, Sebastiano ; Berardi, Rossana</creatorcontrib><description><![CDATA[Specific components of lipid profile seem to differently impact on immune activity against cancer and unraveling their prognostic role in patients with solid cancer treated with immune checkpoint inhibitors (ICIs) is needed.
We retrospectively collected baseline clinicopathological characteristics including circulating lipid profile (total cholesterol [TC], triglycerides [TG], low-density lipoproteins [LDL], high-density lipoproteins [HDL]) of patients with consecutive solid cancer treated with ICIs, and we investigated their role in predicting clinical outcomes.
At a median follow-up of 32.9 months, among 430 enrolled patients, those with TC ≥ 200 mg/dl showed longer median progression-free survival (mPFS; 6.6 vs. 4.7 months, P = .4), although not reaching statistical significance, and significantly longer median overall survival (mOS; 19.4 vs. 10.8 months, P = .02) compared to those with TC < 200 mg/dl. Conversely, patients with TG ≥150 mg/dl displayed shorter PFS (3.4 vs. 5.1 months, P = .02) and OS (7.1 vs. 12.9 months, P = .009) compared to those with TG <150 mg/dl. TC and TG were then combined in a "LIPID score" identifying three subgroups: good-risk (GR) (TC ≥200 mg/dl and TG <150 mg/dl), intermediate-risk (IR) (TC <200 mg/dl and TG <150 mg/dl or TC ≥200 mg/dl and TG ≥150 mg/dl) and poor-risk (PR) (TC <200 mg/dl and TG ≥150 mg/dl). The mPFS of GR, IR, and PR groups was 7.8, 4.3, and 2.5 months, respectively (P = .005); mOS of GR, IR, and PR was 20.4, 12.4, and 5.3 months, respectively (P < .001). At multivariable analysis, the PR profile represented an independent poor prognostic factor for both PFS and OS.
We developed a lipid score that defined subgroups of patients with cancer who differently benefit from ICIs. Further mechanistic insights are warranted to clarify the prognostic and predictive role of lipid profile components in patients treated with ICIs.]]></description><identifier>ISSN: 1083-7159</identifier><identifier>EISSN: 1549-490X</identifier><identifier>DOI: 10.1093/oncolo/oyad273</identifier><identifier>PMID: 37796838</identifier><language>eng</language><publisher>England: Oxford University Press</publisher><subject>Analysis ; Antilipemic agents ; Blood lipids ; Cancer ; Cancer patients ; Development and progression ; Drug therapy ; Health aspects ; Immuno-Oncology ; Immunotherapy ; Low density lipoproteins ; Measurement ; Pharmaceutical industry ; Prognosis ; Triglycerides</subject><ispartof>The oncologist (Dayton, Ohio), 2024-03, Vol.29 (3), p.e372-e381</ispartof><rights>The Author(s) 2023. Published by Oxford University Press.</rights><rights>COPYRIGHT 2024 Oxford University Press</rights><rights>The Author(s) 2023. Published by Oxford University Press. 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c458t-2f5502b9cde403bd8eb4652f158b9a37179b15dc600ca6d0fc44181d8545c97b3</citedby><cites>FETCH-LOGICAL-c458t-2f5502b9cde403bd8eb4652f158b9a37179b15dc600ca6d0fc44181d8545c97b3</cites><orcidid>0000-0002-1209-5735 ; 0000-0002-9529-2960</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10911919/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10911919/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,27903,27904,53770,53772</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37796838$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pecci, Federica</creatorcontrib><creatorcontrib>Cantini, Luca</creatorcontrib><creatorcontrib>Cognigni, Valeria</creatorcontrib><creatorcontrib>Perrone, Fabiana</creatorcontrib><creatorcontrib>Mazzaschi, Giulia</creatorcontrib><creatorcontrib>Agostinelli, Veronica</creatorcontrib><creatorcontrib>Mentrasti, Giulia</creatorcontrib><creatorcontrib>Favari, Elda</creatorcontrib><creatorcontrib>Maffezzoli, Michele</creatorcontrib><creatorcontrib>Cortellini, Alessio</creatorcontrib><creatorcontrib>Rossi, Francesca</creatorcontrib><creatorcontrib>Chiariotti, Rebecca</creatorcontrib><creatorcontrib>Venanzi, Francesco Maria</creatorcontrib><creatorcontrib>Lo Russo, Giuseppe</creatorcontrib><creatorcontrib>Galli, Giulia</creatorcontrib><creatorcontrib>Proto, Claudia</creatorcontrib><creatorcontrib>Ganzinelli, Monica</creatorcontrib><creatorcontrib>Tronconi, Francesca</creatorcontrib><creatorcontrib>Morgese, Francesca</creatorcontrib><creatorcontrib>Campolucci, Carla</creatorcontrib><creatorcontrib>Moretti, Marco</creatorcontrib><creatorcontrib>Vignini, Arianna</creatorcontrib><creatorcontrib>Tiseo, Marcello</creatorcontrib><creatorcontrib>Minari, Roberta</creatorcontrib><creatorcontrib>Rocchi, Marco Luigi Bruno</creatorcontrib><creatorcontrib>Buti, Sebastiano</creatorcontrib><creatorcontrib>Berardi, Rossana</creatorcontrib><title>Prognostic Impact of Blood Lipid Profile in Patients With Advanced Solid Tumors Treated With Immune Checkpoint Inhibitors: A Multicenter Cohort Study</title><title>The oncologist (Dayton, Ohio)</title><addtitle>Oncologist</addtitle><description><![CDATA[Specific components of lipid profile seem to differently impact on immune activity against cancer and unraveling their prognostic role in patients with solid cancer treated with immune checkpoint inhibitors (ICIs) is needed.
We retrospectively collected baseline clinicopathological characteristics including circulating lipid profile (total cholesterol [TC], triglycerides [TG], low-density lipoproteins [LDL], high-density lipoproteins [HDL]) of patients with consecutive solid cancer treated with ICIs, and we investigated their role in predicting clinical outcomes.
At a median follow-up of 32.9 months, among 430 enrolled patients, those with TC ≥ 200 mg/dl showed longer median progression-free survival (mPFS; 6.6 vs. 4.7 months, P = .4), although not reaching statistical significance, and significantly longer median overall survival (mOS; 19.4 vs. 10.8 months, P = .02) compared to those with TC < 200 mg/dl. Conversely, patients with TG ≥150 mg/dl displayed shorter PFS (3.4 vs. 5.1 months, P = .02) and OS (7.1 vs. 12.9 months, P = .009) compared to those with TG <150 mg/dl. TC and TG were then combined in a "LIPID score" identifying three subgroups: good-risk (GR) (TC ≥200 mg/dl and TG <150 mg/dl), intermediate-risk (IR) (TC <200 mg/dl and TG <150 mg/dl or TC ≥200 mg/dl and TG ≥150 mg/dl) and poor-risk (PR) (TC <200 mg/dl and TG ≥150 mg/dl). The mPFS of GR, IR, and PR groups was 7.8, 4.3, and 2.5 months, respectively (P = .005); mOS of GR, IR, and PR was 20.4, 12.4, and 5.3 months, respectively (P < .001). At multivariable analysis, the PR profile represented an independent poor prognostic factor for both PFS and OS.
We developed a lipid score that defined subgroups of patients with cancer who differently benefit from ICIs. Further mechanistic insights are warranted to clarify the prognostic and predictive role of lipid profile components in patients treated with ICIs.]]></description><subject>Analysis</subject><subject>Antilipemic agents</subject><subject>Blood lipids</subject><subject>Cancer</subject><subject>Cancer patients</subject><subject>Development and progression</subject><subject>Drug therapy</subject><subject>Health aspects</subject><subject>Immuno-Oncology</subject><subject>Immunotherapy</subject><subject>Low density lipoproteins</subject><subject>Measurement</subject><subject>Pharmaceutical industry</subject><subject>Prognosis</subject><subject>Triglycerides</subject><issn>1083-7159</issn><issn>1549-490X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNptkkFvFCEYhidGY2v16tGQePEyLQzDzODFrBurm6yxSdfojTDA7KAzfFNgmuwP6f-V7a6NJg0HvsDzvbzAm2WvCT4nmNMLcAoGuICd1EVNn2SnhJU8Lzn--TTVuKF5TRg_yV6E8AvjVNLieXZC65pXDW1Os7srD1sHIVqFVuMkVUTQoY8DgEZrO1mNEtDZwSDr0JWM1rgY0A8be7TQt9Ipo9E1DInbzCP4gDbeyJgW75HVOM7OoGVv1O8JrIto5Xrb2pjI92iBvs5DOjhJGo-W0IOP6DrOevcye9bJIZhXx_ks-375abP8kq-_fV4tF-tclayJedExhouWK21KTFvdmLasWNER1rRc0prUvCVMqwpjJSuNO1WWpCG6YSVTvG7pWfbhoDvN7Wj03omXg5i8HaXfCZBW_L_jbC-2cCvS2xPCCU8K744KHm5mE6IYbVBmGKQzMAdRNHVZVBTTKqFvD-hWDkZY10GSVHtcLGpOGKvxveD5I1Qa2oxWgTP7z3i0QXkIwZvuwT7Be59UHDIijhlJDW_-vfQD_jcU9A_drrw7</recordid><startdate>20240301</startdate><enddate>20240301</enddate><creator>Pecci, Federica</creator><creator>Cantini, Luca</creator><creator>Cognigni, Valeria</creator><creator>Perrone, Fabiana</creator><creator>Mazzaschi, Giulia</creator><creator>Agostinelli, Veronica</creator><creator>Mentrasti, Giulia</creator><creator>Favari, Elda</creator><creator>Maffezzoli, Michele</creator><creator>Cortellini, Alessio</creator><creator>Rossi, Francesca</creator><creator>Chiariotti, Rebecca</creator><creator>Venanzi, Francesco Maria</creator><creator>Lo Russo, Giuseppe</creator><creator>Galli, Giulia</creator><creator>Proto, Claudia</creator><creator>Ganzinelli, Monica</creator><creator>Tronconi, Francesca</creator><creator>Morgese, Francesca</creator><creator>Campolucci, Carla</creator><creator>Moretti, Marco</creator><creator>Vignini, Arianna</creator><creator>Tiseo, Marcello</creator><creator>Minari, Roberta</creator><creator>Rocchi, Marco Luigi Bruno</creator><creator>Buti, Sebastiano</creator><creator>Berardi, Rossana</creator><general>Oxford University Press</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-1209-5735</orcidid><orcidid>https://orcid.org/0000-0002-9529-2960</orcidid></search><sort><creationdate>20240301</creationdate><title>Prognostic Impact of Blood Lipid Profile in Patients With Advanced Solid Tumors Treated With Immune Checkpoint Inhibitors: A Multicenter Cohort Study</title><author>Pecci, Federica ; Cantini, Luca ; Cognigni, Valeria ; Perrone, Fabiana ; Mazzaschi, Giulia ; Agostinelli, Veronica ; Mentrasti, Giulia ; Favari, Elda ; Maffezzoli, Michele ; Cortellini, Alessio ; Rossi, Francesca ; Chiariotti, Rebecca ; Venanzi, Francesco Maria ; Lo Russo, Giuseppe ; Galli, Giulia ; Proto, Claudia ; Ganzinelli, Monica ; Tronconi, Francesca ; Morgese, Francesca ; Campolucci, Carla ; Moretti, Marco ; Vignini, Arianna ; Tiseo, Marcello ; Minari, Roberta ; Rocchi, Marco Luigi Bruno ; Buti, Sebastiano ; Berardi, Rossana</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c458t-2f5502b9cde403bd8eb4652f158b9a37179b15dc600ca6d0fc44181d8545c97b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Analysis</topic><topic>Antilipemic agents</topic><topic>Blood lipids</topic><topic>Cancer</topic><topic>Cancer patients</topic><topic>Development and progression</topic><topic>Drug therapy</topic><topic>Health aspects</topic><topic>Immuno-Oncology</topic><topic>Immunotherapy</topic><topic>Low density lipoproteins</topic><topic>Measurement</topic><topic>Pharmaceutical industry</topic><topic>Prognosis</topic><topic>Triglycerides</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pecci, Federica</creatorcontrib><creatorcontrib>Cantini, Luca</creatorcontrib><creatorcontrib>Cognigni, Valeria</creatorcontrib><creatorcontrib>Perrone, Fabiana</creatorcontrib><creatorcontrib>Mazzaschi, Giulia</creatorcontrib><creatorcontrib>Agostinelli, Veronica</creatorcontrib><creatorcontrib>Mentrasti, Giulia</creatorcontrib><creatorcontrib>Favari, Elda</creatorcontrib><creatorcontrib>Maffezzoli, Michele</creatorcontrib><creatorcontrib>Cortellini, Alessio</creatorcontrib><creatorcontrib>Rossi, Francesca</creatorcontrib><creatorcontrib>Chiariotti, Rebecca</creatorcontrib><creatorcontrib>Venanzi, Francesco Maria</creatorcontrib><creatorcontrib>Lo Russo, Giuseppe</creatorcontrib><creatorcontrib>Galli, Giulia</creatorcontrib><creatorcontrib>Proto, Claudia</creatorcontrib><creatorcontrib>Ganzinelli, Monica</creatorcontrib><creatorcontrib>Tronconi, Francesca</creatorcontrib><creatorcontrib>Morgese, Francesca</creatorcontrib><creatorcontrib>Campolucci, Carla</creatorcontrib><creatorcontrib>Moretti, Marco</creatorcontrib><creatorcontrib>Vignini, Arianna</creatorcontrib><creatorcontrib>Tiseo, Marcello</creatorcontrib><creatorcontrib>Minari, Roberta</creatorcontrib><creatorcontrib>Rocchi, Marco Luigi Bruno</creatorcontrib><creatorcontrib>Buti, Sebastiano</creatorcontrib><creatorcontrib>Berardi, Rossana</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The oncologist (Dayton, Ohio)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pecci, Federica</au><au>Cantini, Luca</au><au>Cognigni, Valeria</au><au>Perrone, Fabiana</au><au>Mazzaschi, Giulia</au><au>Agostinelli, Veronica</au><au>Mentrasti, Giulia</au><au>Favari, Elda</au><au>Maffezzoli, Michele</au><au>Cortellini, Alessio</au><au>Rossi, Francesca</au><au>Chiariotti, Rebecca</au><au>Venanzi, Francesco Maria</au><au>Lo Russo, Giuseppe</au><au>Galli, Giulia</au><au>Proto, Claudia</au><au>Ganzinelli, Monica</au><au>Tronconi, Francesca</au><au>Morgese, Francesca</au><au>Campolucci, Carla</au><au>Moretti, Marco</au><au>Vignini, Arianna</au><au>Tiseo, Marcello</au><au>Minari, Roberta</au><au>Rocchi, Marco Luigi Bruno</au><au>Buti, Sebastiano</au><au>Berardi, Rossana</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prognostic Impact of Blood Lipid Profile in Patients With Advanced Solid Tumors Treated With Immune Checkpoint Inhibitors: A Multicenter Cohort Study</atitle><jtitle>The oncologist (Dayton, Ohio)</jtitle><addtitle>Oncologist</addtitle><date>2024-03-01</date><risdate>2024</risdate><volume>29</volume><issue>3</issue><spage>e372</spage><epage>e381</epage><pages>e372-e381</pages><issn>1083-7159</issn><eissn>1549-490X</eissn><abstract><![CDATA[Specific components of lipid profile seem to differently impact on immune activity against cancer and unraveling their prognostic role in patients with solid cancer treated with immune checkpoint inhibitors (ICIs) is needed.
We retrospectively collected baseline clinicopathological characteristics including circulating lipid profile (total cholesterol [TC], triglycerides [TG], low-density lipoproteins [LDL], high-density lipoproteins [HDL]) of patients with consecutive solid cancer treated with ICIs, and we investigated their role in predicting clinical outcomes.
At a median follow-up of 32.9 months, among 430 enrolled patients, those with TC ≥ 200 mg/dl showed longer median progression-free survival (mPFS; 6.6 vs. 4.7 months, P = .4), although not reaching statistical significance, and significantly longer median overall survival (mOS; 19.4 vs. 10.8 months, P = .02) compared to those with TC < 200 mg/dl. Conversely, patients with TG ≥150 mg/dl displayed shorter PFS (3.4 vs. 5.1 months, P = .02) and OS (7.1 vs. 12.9 months, P = .009) compared to those with TG <150 mg/dl. TC and TG were then combined in a "LIPID score" identifying three subgroups: good-risk (GR) (TC ≥200 mg/dl and TG <150 mg/dl), intermediate-risk (IR) (TC <200 mg/dl and TG <150 mg/dl or TC ≥200 mg/dl and TG ≥150 mg/dl) and poor-risk (PR) (TC <200 mg/dl and TG ≥150 mg/dl). The mPFS of GR, IR, and PR groups was 7.8, 4.3, and 2.5 months, respectively (P = .005); mOS of GR, IR, and PR was 20.4, 12.4, and 5.3 months, respectively (P < .001). At multivariable analysis, the PR profile represented an independent poor prognostic factor for both PFS and OS.
We developed a lipid score that defined subgroups of patients with cancer who differently benefit from ICIs. Further mechanistic insights are warranted to clarify the prognostic and predictive role of lipid profile components in patients treated with ICIs.]]></abstract><cop>England</cop><pub>Oxford University Press</pub><pmid>37796838</pmid><doi>10.1093/oncolo/oyad273</doi><orcidid>https://orcid.org/0000-0002-1209-5735</orcidid><orcidid>https://orcid.org/0000-0002-9529-2960</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1083-7159 |
| ispartof | The oncologist (Dayton, Ohio), 2024-03, Vol.29 (3), p.e372-e381 |
| issn | 1083-7159 1549-490X |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10911919 |
| source | DOAJ Directory of Open Access Journals; Oxford Journals Open Access Collection; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Analysis Antilipemic agents Blood lipids Cancer Cancer patients Development and progression Drug therapy Health aspects Immuno-Oncology Immunotherapy Low density lipoproteins Measurement Pharmaceutical industry Prognosis Triglycerides |
| title | Prognostic Impact of Blood Lipid Profile in Patients With Advanced Solid Tumors Treated With Immune Checkpoint Inhibitors: A Multicenter Cohort Study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T06%3A20%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prognostic%20Impact%20of%20Blood%20Lipid%20Profile%20in%20Patients%20With%20Advanced%20Solid%20Tumors%20Treated%20With%20Immune%20Checkpoint%20Inhibitors:%20A%20Multicenter%20Cohort%20Study&rft.jtitle=The%20oncologist%20(Dayton,%20Ohio)&rft.au=Pecci,%20Federica&rft.date=2024-03-01&rft.volume=29&rft.issue=3&rft.spage=e372&rft.epage=e381&rft.pages=e372-e381&rft.issn=1083-7159&rft.eissn=1549-490X&rft_id=info:doi/10.1093/oncolo/oyad273&rft_dat=%3Cgale_pubme%3EA791557019%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2874263036&rft_id=info:pmid/37796838&rft_galeid=A791557019&rfr_iscdi=true |